Azevan Pharmaceuticals is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Company?s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of Intermittent Explosive Disorder, neuropsychiatric symptoms in neurodegenerative diseases, PTSD, and other affective disorders. Vasopressin 1a receptor antagonists represent a novel mechanism of action for addressing these indications.
The Company's lead clinical candidate, SRX246, is in a Phase II clinical trial for the treatment of Intermittent Explosive Disorder with an expected completion date in Q2 2016. Two additional Phase II clinical trials are being launched in 2016 for the treatment of irritability in Huntington's Disease Patients (Q2) and for the treatment of PTSD (Q2).